Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.66 |
| ▸ | BRAF | P15056 | 10/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | PLK4 | O00444 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 2/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.60 |
| ▸ | ABL1 | P00519 | 2/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | FYN | P06241 | 2/20 | 0.60 |
| ▸ | CSF1R | P07333 | 2/20 | 0.60 |
| ▸ | LYN | P07948 | 2/20 | 0.60 |
| ▸ | MET | P08581 | 2/20 | 0.60 |
| ▸ | KIT | P10721 | 2/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.60 |
| ▸ | FLT1 | P17948 | 2/20 | 0.60 |
| ▸ | MARK3 | P27448 | 2/20 | 0.60 |
| ▸ | FLT4 | P35916 | 2/20 | 0.60 |
| ▸ | FLT3 | P36888 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3531887 | 0.89 | KDR (0.61) | KDRAURKBCYP3A4PLK4AURKA | |
| SCHEMBL3581493 | 0.88 | KDR (0.86) | KDRAURKBBRAFCYP3A4PLK4 | |
| SCHEMBL13708295 | 0.87 | EPHB4 (0.68) | KDRAURKBBRAFPLK4AURKA | |
| SCHEMBL3525217 | 0.86 | BRAF (0.59) | KDRAURKBBRAFCYP3A4FYN | |
| SCHEMBL28757954 | 0.86 | KDR (0.68) | KDRAURKBBRAFCYP3A4PLK4 | |
| SCHEMBL3529846 | 0.84 | KDR (0.69) | KDRAURKBBRAFCYP3A4PLK4 | |
| SCHEMBL3532489 | 0.84 | KDR (0.88) | KDRAURKBCYP3A4PLK4AURKA | |
| SCHEMBL3576965 | 0.84 | KDR (0.55) | KDRAURKBBRAFCYP3A4PLK4 | |
| SCHEMBL3532221 | 0.84 | KDR (0.78) | KDRAURKBCYP3A4PLK4AURKA | |
| SCHEMBL3558774 | 0.83 | KDR (0.89) | KDRAURKBCYP3A4PLK4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103087078-A | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LAB | 2013-05-08 | — | — | CN | disclosed |
| US-8273736-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-7737160-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| CN-1856498-A | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LAB (US) | 2006-11-01 | — | — | CN | disclosed |
| EP-1648905-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | KDR 494/4885AURKB 171/4885BRAF 26/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | KDR 494/4885AURKB 171/4885BRAF 26/4885 |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | KDR 494/4885AURKB 171/4885BRAF 26/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | KDR 494/4885AURKB 171/4885BRAF 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.